Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis

Objective: To compare the efficacy and safety of conventional treatments (CTs) to those that included traditional Chinese medicine injections (TCMIs) in patients with combined coronary heart disease and heart failure (CHD-HF).Methods: Eight electronic literature databases (PubMed, Embase, Cochrane C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Penglu Wei, Kuo Yang, Dehuai Long, Yupei Tan, Wenlong Xing, Xiang Li, Hongli Wu, Hongxu Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	traditional Chinese medicine injection coronary heart disease heart failure network meta-analysis systematic review Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/d4c6632814d042c6ac5070d8f33fc13f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d4c6632814d042c6ac5070d8f33fc13f
record_format	dspace
spelling	oai:doaj.org-article:d4c6632814d042c6ac5070d8f33fc13f2021-11-30T19:21:16ZEfficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis1663-981210.3389/fphar.2021.741261https://doaj.org/article/d4c6632814d042c6ac5070d8f33fc13f2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.741261/fullhttps://doaj.org/toc/1663-9812Objective: To compare the efficacy and safety of conventional treatments (CTs) to those that included traditional Chinese medicine injections (TCMIs) in patients with combined coronary heart disease and heart failure (CHD-HF).Methods: Eight electronic literature databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure Database, Chinese Scientific Journal Database, Wanfang Database, Chinese Biomedical Database) were searched from their inceptions to May 18, 2021, to identify relevant randomised controlled trials (RCTs). The primary outcomes analyzed included the total effectiveness rate and adverse events (ADRs). The secondary outcomes analyzed included the left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-proBNP), brain natriuretic peptide (BNP), and 6-min walk test (6MWT). Cochrane risk-of-bias tool was used to assess quality of the analyzed RCTs. Stata and OpenBUGS software were used to prior to the systematic review and network meta-analysis.Results: Sixty-one eligible trials involved 5,567 patients and one of the following 15 TCMIs: Shuxuetong, Shenmai, Shenfu, Shengmai, Danshenduofenyansuan, Danhong, Dazhuhongjingtian, Xinmailong, Dengzhanxixin, Gualoupi, Shuxuening, Xuesaitong, Yiqi Fumai, Shenqi Fuzheng, Huangqi. Network meta-analysis revealed that Shuxuetong injection + CT group was superior to CT only in improving the total effectiveness rate [odds ratio (OR): 7.8, 95% confidence interval (CI): 1.17–27.41]. Shenmai injection + CT was superior to CT only for LVEF (OR: 8.97, CI: 4.67–13.18), Xinmailong injection + CT was superior to CT only for NT-proBNP (OR: −317.70, CI: −331.10–303.10), Shenqi Fuzheng injection + CT was superior to CT only for BNP (OR: −257.30, CI: −308.40–242.80); and Danhong injection + CT was superior to CT only for 6MWT (OR: 84.40, CI: 62.62−106.20). Different TCMIs had different toxicity spectrums.Conclusion: TCMIs combined with CT are better than CT alone in treating CHD-HF. Different TCMIs improve different outcomes. Additional properly designed RCTs are needed to conduce a more refined comparison of various TCMIs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42021258263].Penglu WeiKuo YangDehuai LongYupei TanWenlong XingXiang LiHongli WuHongxu LiuFrontiers Media S.A.articletraditional Chinese medicine injectioncoronary heart diseaseheart failurenetwork meta-analysissystematic reviewTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	traditional Chinese medicine injection coronary heart disease heart failure network meta-analysis systematic review Therapeutics. Pharmacology RM1-950
spellingShingle	traditional Chinese medicine injection coronary heart disease heart failure network meta-analysis systematic review Therapeutics. Pharmacology RM1-950 Penglu Wei Kuo Yang Dehuai Long Yupei Tan Wenlong Xing Xiang Li Hongli Wu Hongxu Liu Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
description	Objective: To compare the efficacy and safety of conventional treatments (CTs) to those that included traditional Chinese medicine injections (TCMIs) in patients with combined coronary heart disease and heart failure (CHD-HF).Methods: Eight electronic literature databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure Database, Chinese Scientific Journal Database, Wanfang Database, Chinese Biomedical Database) were searched from their inceptions to May 18, 2021, to identify relevant randomised controlled trials (RCTs). The primary outcomes analyzed included the total effectiveness rate and adverse events (ADRs). The secondary outcomes analyzed included the left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-proBNP), brain natriuretic peptide (BNP), and 6-min walk test (6MWT). Cochrane risk-of-bias tool was used to assess quality of the analyzed RCTs. Stata and OpenBUGS software were used to prior to the systematic review and network meta-analysis.Results: Sixty-one eligible trials involved 5,567 patients and one of the following 15 TCMIs: Shuxuetong, Shenmai, Shenfu, Shengmai, Danshenduofenyansuan, Danhong, Dazhuhongjingtian, Xinmailong, Dengzhanxixin, Gualoupi, Shuxuening, Xuesaitong, Yiqi Fumai, Shenqi Fuzheng, Huangqi. Network meta-analysis revealed that Shuxuetong injection + CT group was superior to CT only in improving the total effectiveness rate [odds ratio (OR): 7.8, 95% confidence interval (CI): 1.17–27.41]. Shenmai injection + CT was superior to CT only for LVEF (OR: 8.97, CI: 4.67–13.18), Xinmailong injection + CT was superior to CT only for NT-proBNP (OR: −317.70, CI: −331.10–303.10), Shenqi Fuzheng injection + CT was superior to CT only for BNP (OR: −257.30, CI: −308.40–242.80); and Danhong injection + CT was superior to CT only for 6MWT (OR: 84.40, CI: 62.62−106.20). Different TCMIs had different toxicity spectrums.Conclusion: TCMIs combined with CT are better than CT alone in treating CHD-HF. Different TCMIs improve different outcomes. Additional properly designed RCTs are needed to conduce a more refined comparison of various TCMIs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42021258263].
format	article
author	Penglu Wei Kuo Yang Dehuai Long Yupei Tan Wenlong Xing Xiang Li Hongli Wu Hongxu Liu
author_facet	Penglu Wei Kuo Yang Dehuai Long Yupei Tan Wenlong Xing Xiang Li Hongli Wu Hongxu Liu
author_sort	Penglu Wei
title	Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
title_short	Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
title_full	Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
title_fullStr	Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
title_full_unstemmed	Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
title_sort	efficacy and safety of tcmi in patients with combined coronary heart disease and heart failure: a systematic review and network meta-analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d4c6632814d042c6ac5070d8f33fc13f
work_keys_str_mv	AT pengluwei efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT kuoyang efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT dehuailong efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT yupeitan efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT wenlongxing efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT xiangli efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT hongliwu efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis AT hongxuliu efficacyandsafetyoftcmiinpatientswithcombinedcoronaryheartdiseaseandheartfailureasystematicreviewandnetworkmetaanalysis
_version_	1718406352974381056

Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis

Ejemplares similares